MedTrace Logo

Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585

NCT02746237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-08-30

No results posted yet for this study

Summary

Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.

Conditions

Interventions

DRUG

KAR5585 Capsules

Single and multiple ascending doses of KAR5585 (100 mg initial dose)

DRUG

Placebo Capsules

Single and multiple ascending doses of placebo (100 mg initial dose)

Sponsors & Collaborators

  • Karos Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Carlos Sanabria, MD · Spaulding Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02746237 on ClinicalTrials.gov